Liver Injury
Drug R&D Solutions

Liver Injury

Inquiry

Liver injury, also referred to as hepatic injury, encompasses a spectrum of pathological conditions in which liver cells (hepatocytes) are damaged due to a variety of insults. The liver, a central organ in metabolism, detoxification, and synthesis of vital proteins, is susceptible to damage from toxins, drugs, infections, ischemia, autoimmune responses, and metabolic disturbances. The pathogenesis of liver injury involves direct cellular toxicity, immune-mediated mechanisms, oxidative stress, and mitochondrial dysfunction, leading to hepatocyte apoptosis or necrosis. As hepatocytes are damaged, the release of intracellular enzymes and inflammatory mediators can propagate further injury and disrupt normal liver architecture and function. The clinical consequences of liver injury range from asymptomatic elevations in liver enzymes to acute liver failure, with potential for chronic sequelae such as fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma. Health impacts are significant, as liver injury can compromise metabolic homeostasis, coagulation, detoxification, and immune regulation, leading to morbidity and mortality if not promptly recognized and managed.

Drug-Induced Liver Injury (Dili)

Drug-induced liver injury is a form of hepatic damage resulting from exposure to pharmaceutical agents, herbal supplements, or toxins. DILI can be categorized as intrinsic (predictable and dose-dependent, such as acetaminophen toxicity) or idiosyncratic (unpredictable and not clearly dose-related). The clinical presentation varies from mild, transient elevations in liver enzymes to fulminant hepatic failure. Pathologically, DILI can manifest as hepatocellular, cholestatic, or mixed injury patterns, depending on the agent involved and individual susceptibility.

Ischemic Hepatitis

Ischemic hepatitis, also known as shock liver, arises from a sudden reduction in hepatic blood flow, often secondary to systemic hypotension, cardiac failure, or septic shock. The resultant hypoxia leads to centrilobular hepatocyte necrosis. Patients typically present with abrupt, marked elevations in aminotransferases, and the condition is frequently reversible if the underlying circulatory disturbance is corrected.

Viral Hepatitis-Associated Liver Injury

Liver injury due to viral hepatitis is caused by infection with hepatotropic viruses such as hepatitis A, B, C, D, and E. The pathogenesis involves direct viral cytopathic effects and immune-mediated destruction of infected hepatocytes. The spectrum ranges from acute hepatitis with jaundice to chronic hepatitis, which may progress to cirrhosis and hepatocellular carcinoma.

Autoimmune Hepatitis

Autoimmune hepatitis is a chronic inflammatory liver disease characterized by immune-mediated destruction of hepatocytes. It is associated with autoantibodies and elevated immunoglobulins. Clinical manifestations range from asymptomatic to fulminant hepatic failure, and histology typically reveals interface hepatitis with lymphoplasmacytic infiltrate.

Alcoholic Liver Injury

Alcoholic liver injury results from excessive and chronic consumption of ethanol, leading to a continuum from steatosis (fatty liver) to steatohepatitis, fibrosis, and ultimately cirrhosis. The pathogenesis involves oxidative stress, acetaldehyde toxicity, and inflammatory cytokine production. Clinical features may include hepatomegaly, jaundice, and signs of portal hypertension in advanced cases.

Epidemiology

Liver injury is a substantial global health concern, with its epidemiology varying by etiology and geographic region. Drug-induced liver injury is the leading cause of acute liver failure in many developed countries, with an estimated incidence of 10–15 cases per 100,000 persons annually, and acetaminophen being the most common culprit. Ischemic hepatitis accounts for approximately 1–2% of acute liver injury cases in hospitalized patients, often associated with critical illness. Viral hepatitis remains a major cause of liver injury worldwide; chronic hepatitis B and C affect over 350 million and 70 million people, respectively, leading to significant morbidity and mortality. Autoimmune hepatitis is less common, with an estimated prevalence of 10–20 per 100,000 in Western populations, predominantly affecting women. Alcoholic liver disease is a leading cause of cirrhosis and liver-related deaths, with a global prevalence of alcohol use disorders exceeding 5%. The burden of liver injury is compounded by rising rates of obesity, diabetes, and nonalcoholic fatty liver disease, further increasing the risk of hepatic complications.

Diagnosis

The diagnosis of liver injury involves a combination of clinical evaluation, laboratory testing, imaging, and sometimes histopathological examination. Initial assessment includes a thorough history focused on exposures (medications, toxins, alcohol), risk factors (viral hepatitis, autoimmune disease), and clinical symptoms (jaundice, right upper quadrant pain, fatigue). Laboratory evaluation typically reveals elevations in serum aminotransferases (ALT, AST), alkaline phosphatase, and bilirubin, with the pattern of enzyme derangement providing clues to the type of injury (hepatocellular vs. cholestatic). Additional tests may include coagulation studies (INR, PT), albumin, and markers of hepatic synthetic function. Serologic tests for viral hepatitis, autoimmune markers (ANA, SMA, LKM), and toxicology screens may be warranted based on clinical suspicion. Imaging modalities such as abdominal ultrasound, CT, or MRI are used to evaluate liver morphology, exclude biliary obstruction, and assess for complications. In selected cases, liver biopsy may be necessary to confirm the diagnosis, assess severity, or guide management. Diagnostic criteria for specific types of liver injury, such as drug-induced liver injury, may involve temporal association with drug exposure, exclusion of alternative causes, and application of causality assessment tools (e.g., RUCAM scale).

Launched Drugs

Acetylcysteine is utilized in the management of liver injury, particularly in cases of acetaminophen-induced hepatotoxicity. This agent acts as a precursor to glutathione, facilitating the detoxification of reactive metabolites and thereby mitigating hepatic cellular damage. Early administration of acetylcysteine has been shown to significantly improve outcomes by reducing the severity of liver injury and preventing progression to acute liver failure. In clinical practice, acetylcysteine is administered orally or intravenously, with dosing regimens tailored to the timing and extent of acetaminophen exposure. Its efficacy is most pronounced when initiated within eight hours of overdose, but it may also confer benefits in late-presenting cases and in non-acetaminophen acute liver failure by supporting antioxidant defenses and modulating inflammatory responses.

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-616-91-1-acetylcysteine-rec-inn-usan-bann-acetyl-l-cysteine acetylcysteine (Rec INN; USAN; BAN); N-acetyl-L-cysteine (JAN); N-acetylcysteine 616-91-1 C5 H9 N O3 S 163.195
HOW WE WORK

Make Order

Make Order

Experimental Scheme

Experimental Scheme

Implementation

Implementation

Conclusion

Conclusion
Make an Inquiry